ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormone- induced indications; and VAL401 (Phase II) – a novel reformulation of risperidone, in trials for lung cancer. ValiRx has released early analysis of its Phase II trial with VAL 401 in lung cancer patients. The pharmacokinetic data are positive and strengthen the commercial package for out-licensing. Final read-out is due by year-end.
If you'd like to be introduced to the team at ValiRx, get in touch.Request a meeting